Overview
Venture capital firm focused on life sciences investments.
Founded
1985
Deals ยท 12mo
0
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Epic Sciences | Apr 2023Participated | $24 MSeries G | |
Antios Therapeutics | Nov 2021Participated | $75 MSeries B | |
Axial Biotherapeutics | Oct 2021Participated | $37 MSeries C | |
Seraphina Therapeutics | Oct 2021Led | $5 MSeries A | |
Antios Therapeutics | Apr 2021Participated | $96 MSeries B | |
Fractyl Health | Aug 2020Participated | $55 MSeries E | |
Aspen Neuroscience | Apr 2020Participated | $70 MSeries A | |
Omniome | Jan 2020Participated | $60 MSeries C | |
ChromaCode | Dec 2019Participated | $28 MSeries C | |
Aspen Neuroscience | Dec 2019Led | $7 MSeed | |
Truvian Sciences | Nov 2019Participated | $27 MSeries B | |
Sera Prognostics | Nov 2019Participated | $36 MSeries D | |
Epic Sciences | Apr 2023Participated | $24 MSeries G | |
Antios Therapeutics | Nov 2021Participated | $75 MSeries B | |
Axial Biotherapeutics | Oct 2021Participated | $37 MSeries C | |
Seraphina Therapeutics | Oct 2021Led | $5 MSeries A | |
Antios Therapeutics | Apr 2021Participated | $96 MSeries B | |
Fractyl Health | Aug 2020Participated | $55 MSeries E | |
Aspen Neuroscience | Apr 2020Participated | $70 MSeries A | |
Omniome | Jan 2020Participated | $60 MSeries C | |
ChromaCode | Dec 2019Participated | $28 MSeries C | |
Aspen Neuroscience | Dec 2019Led | $7 MSeed | |
Truvian Sciences | Nov 2019Participated | $27 MSeries B | |
Sera Prognostics | Nov 2019Participated | $36 MSeries D |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 1 | 0 |
| Series A | 4 | 6 |
| Series B | 12 | 24 |
| Series C+ | 3 | 43 |
| Other Equity | 3 | 15 |
| Debt | 0 | 2 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Aug '06 | 1 |
| Sep '06 | 0 |
| Oct '06 | 1 |
| Nov '06 | 0 |
| Dec '06 | 0 |
| Jan '07 | 0 |
| Feb '07 | 0 |
| Mar '07 | 1 |
| Apr '07 | 0 |
| May '07 | 1 |
| Jun '07 | 0 |
| Jul '07 | 0 |
| Aug '07 | 1 |
| Sep '07 | 0 |
| Oct '07 | 0 |
| Nov '07 | 0 |
| Dec '07 | 0 |
| Jan '08 | 0 |
| Feb '08 | 0 |
| Mar '08 | 1 |
| Apr '08 | 0 |
| May '08 | 0 |
| Jun '08 | 0 |
| Jul '08 | 0 |
| Aug '08 | 0 |
| Sep '08 | 0 |
| Oct '08 | 0 |
| Nov '08 | 0 |
| Dec '08 | 0 |
| Jan '09 | 0 |
| Feb '09 | 0 |
| Mar '09 | 0 |
| Apr '09 | 0 |
| May '09 | 0 |
| Jun '09 | 0 |
| Jul '09 | 0 |
| Aug '09 | 0 |
| Sep '09 | 1 |
| Oct '09 | 0 |
| Nov '09 | 1 |
| Dec '09 | 4 |
| Jan '10 | 1 |
| Feb '10 | 0 |
| Mar '10 | 1 |
| Apr '10 | 1 |
| May '10 | 3 |
| Jun '10 | 1 |
| Jul '10 | 1 |
| Aug '10 | 3 |
| Sep '10 | 3 |
| Oct '10 | 2 |
| Nov '10 | 0 |
| Dec '10 | 0 |
| Jan '11 | 0 |
| Feb '11 | 2 |
| Mar '11 | 2 |
| Apr '11 | 2 |
| May '11 | 0 |
| Jun '11 | 1 |
| Jul '11 | 0 |
| Aug '11 | 1 |
| Sep '11 | 0 |
| Oct '11 | 0 |
| Nov '11 | 1 |
| Dec '11 | 2 |
| Jan '12 | 2 |
| Feb '12 | 0 |
| Mar '12 | 1 |
| Apr '12 | 0 |
| May '12 | 1 |
| Jun '12 | 2 |
| Jul '12 | 3 |
| Aug '12 | 0 |
| Sep '12 | 2 |
| Oct '12 | 1 |
| Nov '12 | 1 |
| Dec '12 | 2 |
| Jan '13 | 1 |
| Feb '13 | 1 |
| Mar '13 | 0 |
| Apr '13 | 1 |
| May '13 | 0 |
| Jun '13 | 0 |
| Jul '13 | 2 |
| Aug '13 | 3 |
| Sep '13 | 1 |
| Oct '13 | 2 |
| Nov '13 | 1 |
| Dec '13 | 2 |
| Jan '14 | 0 |
| Feb '14 | 2 |
| Mar '14 | 0 |
| Apr '14 | 2 |
| May '14 | 0 |
| Jun '14 | 0 |
| Jul '14 | 1 |
| Aug '14 | 0 |
| Sep '14 | 2 |
| Oct '14 | 0 |
| Nov '14 | 1 |
| Dec '14 | 0 |
| Jan '15 | 2 |
| Feb '15 | 0 |
| Mar '15 | 0 |
| Apr '15 | 0 |
| May '15 | 0 |
| Jun '15 | 3 |
| Jul '15 | 1 |
| Aug '15 | 1 |
| Sep '15 | 0 |
| Oct '15 | 0 |
| Nov '15 | 1 |
| Dec '15 | 0 |
| Jan '16 | 1 |
| Feb '16 | 0 |
| Mar '16 | 0 |
| Apr '16 | 0 |
| May '16 | 0 |
| Jun '16 | 0 |
| Jul '16 | 0 |
| Aug '16 | 0 |
| Sep '16 | 1 |
| Oct '16 | 0 |
| Nov '16 | 2 |
| Dec '16 | 0 |
| Jan '17 | 1 |
| Feb '17 | 0 |
| Mar '17 | 0 |
| Apr '17 | 2 |
| May '17 | 2 |
| Jun '17 | 0 |
| Jul '17 | 1 |
| Aug '17 | 1 |
| Sep '17 | 0 |
| Oct '17 | 0 |
| Nov '17 | 1 |
| Dec '17 | 0 |
| Jan '18 | 0 |
| Feb '18 | 0 |
| Mar '18 | 0 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 1 |
| Jul '18 | 1 |
| Aug '18 | 0 |
| Sep '18 | 0 |
| Oct '18 | 1 |
| Nov '18 | 1 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 1 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 0 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 2 |
| Dec '19 | 2 |
| Jan '20 | 1 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 1 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 1 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 1 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 2 |
| Nov '21 | 1 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 1 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 111 |
| Manufacturing | 8 |
| Consumer & Lifestyle | 4 |
| Fintech | 2 |
| Space & Frontier Tech | 2 |
| Enterprise Software | 1 |
| E-Commerce & Retail | 1 |
| Professional Services | 1 |
| Data, Analytics & IT | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 3 |
| $5M-$10M | 7 |
| $10M-$25M | 37 |
| $25M-$50M | 45 |
| $50M-$100M | 21 |
| $100M-$250M | 0 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 4 of 4 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 106 |
| Canada | 5 |
| Europe | 1 |
| Hong Kong | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Versant Ventures | 17 |
| RusnanoMedInvest | 11 |
| InterWest Partners | 10 |
| Frazier Healthcare Partners | 9 |
| ARCH Venture Partners | 8 |
| OrbiMed | 8 |
| Canaan Partners | 7 |
| TPG Biotech | 7 |
| Abingworth | 6 |
| BDC Capital | 6 |
| Delphi Ventures | 6 |
| New Enterprise Associates | 6 |
| Aisling Capital | 5 |
| Fonds de solidarit FTQ | 5 |
| Johnson & Johnson Innovation | 5 |
| Pappas Ventures | 5 |
| Quaker Partners | 5 |
| Thomas, McNerney & Partners | 5 |
| Alta Partners | 4 |
| Avalon Ventures | 4 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 23 | 20% |
| Participating | 90 | 80% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 11 | 48% |
| Co-led | 12 | 52% |
Team
Partner
Partner
Venture Capitalist
Partner
Founding Partner
Partner
Partner & CFO
Partner
